Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04KTI
|
|||
| Drug Name |
LY3127804
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN angiopoietin-2 (ANG-2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04342897) A Study of LY3127804 in Participants With COVID-19. U.S. National Institutes of Health. | |||
| REF 2 | Updates: Lilly's Global COVID-19 Response | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.